Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | RARA | P10276 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6139910 | 0.98 | RARB (0.58) | RARBALDH1A1KMT2AMEN1RARA | |
| SCHEMBL11359808 | 0.96 | RARB (0.62) | RARBALDH1A1KMT2AMEN1RARA | |
| SCHEMBL83677 | 0.87 | ALDH1A1 (0.56) | RARBALDH1A1KMT2AMEN1RARA | |
| SCHEMBL133470 | 0.87 | RARB (0.68) | RARBALDH1A1KMT2AMEN1RARA | |
| SCHEMBL371605 | 0.87 | RARB (0.71) | RARBALDH1A1KMT2AMEN1RARA | |
| SCHEMBL1560685 | 0.86 | RARB (0.53) | RARBALDH1A1KMT2AMEN1RARA | |
| SCHEMBL27786791 | 0.85 | THRA (0.50) | RARBMAPTTHRATHRBHSD17B10 | |
| Bromide SCHEMBL27719615 | 0.85 | ALDH1A1 (0.54) | RARBALDH1A1KMT2AMEN1RARA | |
| SCHEMBL30053056 | 0.85 | RARB (0.72) | RARBALDH1A1KMT2AMEN1RARA | |
| SCHEMBL28873230 | 0.85 | RARB (0.72) | RARBALDH1A1KMT2AMEN1RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118420855-A | Polyelectrolyte material with high alkali resistance and high conductivity | 广东鸣洋科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-116987061-A | 4-methyl quinazoline derivative, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2023-11-03 | — | — | CN | disclosed |
| CN-102757444-B | There is the benzofuran compounds of nitric oxide donors character | NANJING XINNUOTHAI PHARMACEUTICAL CO., LTD. (CN) | 2016-02-10 | — | — | CN | disclosed |
| CN-102757444-A | Benzofuran compound with nitrous oxide donor property | JIANGSU SIMCERE PHARM RES CO | 2012-10-31 | — | — | CN | disclosed |
| US-8008296-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2322506-A1 | Histamine H3 receptor agents, preparation and therapeutic uses | Eli Lilly and Company (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100160319-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | BEAVERS LISA SELSAM | 2010-06-24 | — | — | US | disclosed |
| EP-1904442-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007005503-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-01-11 | — | — | WO | disclosed |
| CN-1246315-C | Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, process for their preparation and compositions containing them | SANOFI SYNTHELABO (FR) | 2006-03-22 | — | — | CN | disclosed |
| US-4711900-A | LIPOXYGENASE INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1987-12-08 | — | — | US | disclosed |
| US-4469865-A | INHIBITORS OF THROMBOXANE SYNTHETASE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1984-09-04 | — | — | US | disclosed |
| EP-0076140-A2 | 1,3-Disubstituted imidazoles and a process for their production | Kissei Pharmaceutical Co. Ltd. (JP) | 1983-04-06 | — | — | EP | disclosed |
| US-4175203-A | TREATMENT OF RENAL FAILURE AND TRANSPLANT REJECTION VASODILATORS | MERCK & CO., INC. (US) | 1979-11-20 | — | — | US | disclosed |
| US-4150235-A | ANTIBODY INHIBITORS, HYPOTENSIVE AGENTS, DIURETICS, VASODILATOR | MERCK & CO., INC. (US) | 1979-04-17 | — | — | US | disclosed |
| US-4140861-A | RENAL DISFUNCTION, ANTIBODY INHIBITORS | MERCK & CO., INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4112236-A | Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins | MERCK & CO., INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4097496-A | ANTIPROSTAGLANDIN ACTIVITY | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-27 | — | — | US | disclosed |
| US-4083990-A | ANTIPROSTAGLANDIN EFFECT | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-04-11 | — | — | US | disclosed |
| US-3984459-A | ANTI-PROSTAGLANDINS | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160319-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | RARB 3007/4885ALDH1A1 2259/4885KMT2A 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.